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Abstract
Background: Sustained low efficiency dialysis (SLED) is increasingly used as a renal replacement modality in
critically ill patients with acute kidney injury (AKI) and hemodynamic instability. SLED may reduce the hemodynamic
perturbations of intermittent hemodialysis, while obviating the resource demands of CRRT. Although SLED is being
increasingly used, few studies have evaluated its impact on clinical outcomes.
Methods: We conducted a cohort study comparing SLED (target 8 h/session, blood flow 200 mL/min,
predominantly without anticoagulation) to CRRT in four ICUs at an academic medical centre. The primary outcome
was mortality 30 days after RRT initiation, adjusted for demographics, comorbidity, baseline kidney function, and
Sequential Organ Failure Assessment score. Secondary outcomes were persistent RRT dependence at 30 days and
early clinical deterioration, defined as a rise in SOFA score or death 48 h after starting RRT.
Results: We identified 158 patients who initiated treatment with CRRT and 74 with SLED. Mortality at 30 days was
54 % and 61 % among SLED- and CRRT-treated patients, respectively [adjusted odds ratio (OR) 1.07, 95 % CI 0.56–2.03,
as compared with CRRT]. Among SLED recipients, the risk of RRT dependence at 30 days (adjusted OR 1.36, 95 % CI
0.51–3.57) and early clinical deterioration (adjusted OR 0.73, 95 % CI 0.40–1.34) were not different as compared to
patients who initiated CRRT.
Conclusions: Notwithstanding the limitations of this small non-randomized study, we found similar clinical outcomes
for patients treated with SLED and CRRT. While we await the completion of a trial that will definitively assess the
non-inferiority of SLED as compared to CRRT, SLED appears to be an acceptable alternative form of renal support
in hemodynamically unstable patients with AKI.
Background
There is ongoing controversy about the optimal modal-
ity for the delivery of renal replacement therapy (RRT)
to critically ill patients with acute kidney injury (AKI).
Continuous renal replacement therapy (CRRT), which
permits gradual fluid and solute removal, has been asso-
ciated with greater hemodynamic stability and a higher
likelihood of kidney recovery as compared to standard
intermittent hemodialysis [1–3]. However, the logistic
burdens of administering CRRT, including the need for
anticoagulation and specialized pre-manufactured solu-
tions, and overall higher costs, as well as the need to fre-
quently interrupt therapy to allow for off-unit testing
and procedures, detract from the theoretical benefits of
this modality [4, 5]. Moreover, randomized trials have
not demonstrated better patient- or kidney- survival
with CRRT as compared to conventional intermittent
dialysis [6].
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Sustained low-efficiency dialysis (SLED), in which con-
ventional hemodialysis machines are used to provide ex-
tended duration RRT (8 – 12 h vs 3-4 h with classic
intermittent hemodialysis), has emerged as an alternative
to CRRT for patients with hemodynamic instability.
Whereas CRRT often necessitates some form of anticoa-
gulation to prevent filter clotting, SLED may be readily
performed with no anticoagulation. A session of SLED,
especially if performed during the overnight hours, may
be scheduled around tests and procedures and is thus
less likely to be interrupted. Observational studies have
suggested comparable clinical outcomes, and in some
cases lower costs, in patients treated with SLED as com-
pared to CRRT [7–12]. A recently published randomized
trial of SLED vs CRRT that focused on clinical outcomes
was difficult to interpret as the two forms of RRT were
administered in an unconventional manner [13].
We conducted a retrospective cohort study comparing
SLED and CRRT using a comprehensive registry of critically
ill adults with AKI who received RRT. The primary out-
come was all-cause mortality at 30 days after RRT initiation.
Methods
Data sources and study population
Patients were identified from the St. Michael’s Hospital
Acute Kidney Injury Registry, which comprises all adults
who commenced RRT for AKI in the hospital’s four inten-
sive care units (medical-surgical, cardiovascular, trauma-
neurosurgical or coronary care), between April 2007 and
September 2012. AKI was defined by the Acute Kidney In-
jury Network (AKIN) criteria [14]: minimum creatinine
increase of 27 μmol/L or 50 % rise from baseline (if base-
line ≥ 354, then a rise of 44 μmol/L qualified for a diagno-
sis of AKI). Patients with pre-existing end-stage renal
disease who were erroneously entered in the Registry were
excluded. We also excluded patients who initiated RRT
using intermittent hemodialysis (IHD) because at our
institution, IHD is reserved for patients who are
hemodynamically stable whereas SLED or CRRT are
deployed in patients with perceived hemodynamic in-
stability. We restricted this analysis to patients for
whom we could ascertain vital status at 30 days
following the initiation of RRT.
Our study was approved by the Research Ethics Board
of St. Michael’s Hospital. The need for patient-level con-
sent was waived by the Research Ethics Board.
Exposure definition
Initial RRT modality, SLED versus CRRT, was the expos-
ure of interest. Choice of initial RRT modality was made
at the discretion of the consulting nephrologist in collab-
oration with the attending critical care physician. In the
absence of compelling clinical or personnel concerns,
hospital policy discouraged switches between CRRT and
SLED.
Description of administered therapies
CRRT was administered by ICU nurses as continuous
venovenous hemodiafiltration or continuous venovenous
hemofiltration using Prisma and Prismaflex (Gambro,
Richmond Hill, ON) devices. AN-69-based filters were
utilized, with blood flows ranging from 100 – 200 mL/hr
and target effluent rates of 20 – 35 mL/kg/hr.
SLED was introduced as an alternative to CRRT in
2007. Both modalities were targeted to hemodynamically
unstable patients. SLED was delivered by dialysis nurses
using PhoenixTM dialysis machines (Gambro, Richmond
Hill, ON) and CA210 or Xenium 210 dialyzers (Baxter,
Deerfield, IL). SLED sessions were targeted to 8 h in dur-
ation (minimum 6 h) with blood and dialysate flows of
200 and 350 mL/min, respectively. The minimum fre-
quency of SLED treatments was three times per week but
could be increased at the nephrology team’s discretion.
The nephrology consultation service, comprising trainees
who were supervised by an attending nephrologist, pre-
scribed all CRRT and SLED treatments.
Data collection and baseline characteristics
We obtained the following data from the St. Michael’s
Hospital Acute Kidney Injury Registry: patient age and
gender; reason for ICU admission; pre-morbid kidney
function (derived from the abbreviated Modification of
Diet in Renal Disease formula [15] using the last available
pre-hospitalization serum creatinine); Charlson comorbid-
ity score [16]; and the following parameters at the time of
RRT initiation: basic biochemistry and hematologic values;
urine output, receipt of mechanical ventilation, require-
ment for vasopressors and the Sequential Organ Failure
Assessment (SOFA) score [17] (as modified for use in the
Registry [18], see Additional file 1) at the time of RRT initi-
ation. The SOFA score was also recorded at 48 h following
RRT initiation.
Outcomes
The primary outcome was all-cause mortality at 30 days
following RRT initiation. Secondary outcomes included
RRT dependence at 30 days, cumulative fluid removal
seven days following initiation of RRT, and early clinical
deterioration, defined as death or increase in SOFA
score within 48 h of RRT initiation)
Statistical analyses
We expressed continuous variables as means [standard
deviations (SD)] or medians [interquartile range (IQR)],
as appropriate, and categorical variables as numbers
(percentages). The characteristics of patients who initi-
ated SLED vs CRRT were compared using the t-test,
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Mann-Whitney U test or Fisher’s exact test. Logistic re-
gression was used to evaluate the relationship between
RRT modality (SLED versus CRRT) and the outcomes of
interest. For the primary outcome of mortality at 30 days,
we adjusted for age, sex, ICU type, Charlson score,
mechanical ventilation and vasopressor status, serum
creatinine at the time of RRT initiation, SOFA score and
urine output at the time of RRT initiation. These covari-
ates were chosen based on clinical relevance. For the
secondary outcomes for which there were fewer events,
we adjusted our models for baseline serum creatinine,
SOFA score, urine output at the time of RRT initiation
and Charlson score.
Additional analyses
We examined the primary outcome in a subgroup ana-
lysis wherein we stratified patients by initial SOFA score
(less than vs greater than or equal to the median value
of 16) to determine whether severity of illness modified
the relationship between modality and 30-day mortality.
Since switches in RRT modality (eg, SLED to CRRT)
may misclassify the exposure and dilute the association
between initial RRT modality and clinical outcomes, we
conducted two sensitivity analyses. In the first, we desig-
nated RRT modality as the one used for the majority of
treatment sessions received from the initiation of RRT
through Day 30. In the second, we restricted the cohort
to patients who remained on a consistent modality for
the first three RRT sessions.
We performed all analyses using SAS software version
9.1.3 (SAS Institute Inc., Cary, NC).
Results
The steps that led to assembly of the analytic cohort are
presented in Fig. 1. We identified 562 patients within
our AKI Registry at the time of analysis. Of these, we ex-
cluded 227 patients who initiated RRT with IHD and 86
patients received their first RRT treatment in a non-ICU
setting. Other reasons for exclusion were the mistaken
inclusion of patients commencing RRT for ESRD (n = 3);
RRT initiation at an outside facility (n = 3); the receipt of
isolated ultrafiltration as the initial RRT modality (n = 3);
or missing information on initial modality or outcome
(n = 8) (Fig. 1). Among the remaining 232 patients, 158
patients received CRRT as their initial RRT modality,
and 74 received SLED.
Baseline characteristics
Baseline characteristics, stratified by initial receipt of
SLED or CRRT, are presented in Table 1. Patients who
initiated CRRT had higher Charlson (2.61 ± 2.53 versus
1.79 ± 1.77 for SLED recipients, p = 0.03) and SOFA(16.4
± 3.08 versus 15.4 ± 3.65 for SLED recipients, p = 0.03)
scores at the time of RRT initiation and were more likely
to be mechanically ventilated (96.5 versus 85.6 % of SLED
recipients, p = 0.03).
RRT Treatment characteristics
We examined 1107 treatment sessions (698 CRRT and
509 SLED sessions) to characterize the RRT delivered to
members of the cohort. The median duration of SLED
sessions was 7.11 h (IQR 6.00–7.92). On average, 91.9 %
(SD 1.7 %) of the prescribed SLED treatment duration
was delivered. The mean proportion of prescribed CRRT
time that was actually delivered was 84.8 % (SD 22.0 %),
which is compatible with 20.3 h in a 24-h period. SLED
was delivered without use of anticoagulation in 86 % of
treatment sessions, compared to 6 % of CRRT sessions.
Further information on the delivered therapies is shown
in Table 2.
Fig. 1 Study Flow Diagram
Kitchlu et al. BMC Nephrology  (2015) 16:127 Page 3 of 8
Table 1 Baseline characteristics
Variable CRRT (n = 158) SLED (n = 74) p Value
Age at initiation of RRT 62.1 ± 15.3 60.6 ± 17.3 0.50
Male (%) 94 (59.5) 50 (67.6) 0.25
Transferred from another institution (%) 65 (41.1) 35 (47.3) 0.40




Cardiac surgery 42 (26.6) 13 (17.6) 0.14
AAA repair 5 (3.16) 3 (4.05) 0.71
Mean Charlson score 2.61 ± 2.54 1.80 ± 1.77 0.03
Charlson score (categories)
0 28 (17.7) 18 (24.3) 0.22
1 34 (21.5) 20 (27.0)
≥2 96 (60.8) 36 (48.7)
Mechanical ventilation 151 (95.6) 64 (86.5) 0.03
Vasopressors 138 (87.3) 59 (79.7) 0.17
SOFA score 16.4 ± 3.08 15.4 ± 3.65 0.03
Pre-morbid serum creatininea, μmol/L 130.7 ± 91.7 135.3 ± 83.8 0.57
Admission creatinine, μmol/L 185.7 ± 181.5 214.0 ± 202.1 0.75
Admission BUN, mmol/L 13.5 ± 10.8 14.0 ± 11.7 0.89
ICU admission creatinine, μmol/L 225.6 ± 173.4 259.6 ± 192.1 0.11
Creatinine, μmol/L 328.9 ± 136.1 365.1 ± 146.7 0.07
BUN, mmol/L 23.1 ± 11.7 22.3 ± 12.5 0.68
Proportion with BUN≥ 40 mmol/L 15 (10.3) 7 (11.1) 0.87
SBP, mmHg 109.3 ± 20.8 110.9 ± 17.5 0.56
DBP, mmHg 54.5 ± 11.3 57.2 ± 11.5 0.10
Urine output on day of RRT initiation, mL 328.8 ± 580.5 387.6 ± 607.0 0.48
Urine output < 400 mL/24 hrs 126 (80.0) 51 (68.9) 0.07
Hemoglobin, g/L 85.9 ± 14.2 89.7 ± 20.0 0.15
WBC, x 109/L 16.4 ± 11.4 16.7 ± 18.3 0.89
Platelets, x 109/L 134.0 ± 103.7 153.6 ± 104.2 0.18
Sodium, mmol/L 137.7 ± 5.92 136.8 ± 6.80 0.31
Potassium, mmol/L 4.60 ± 0.84 4.65 ± 0.80 0.69
Proportion with potassium≥ 6 mmol/L 12 (7.6) 5 (6.8) 0.82
Bicarbonate, mmol/L 18.6 ± 5.5 19.2 ± 5.0 0.43
Proportion with bicarbonate < 15 mmol/L 32 (20.2) 12 (16.2) 0.46
Glucose, mmol/L 7.73 ± 3.38 7.71 ± 3.35 0.96
Lactate, mmol/L 4.62 ± 4.76 4.50 ± 5.13 0.87
Bilirubin, mmol/L 59.9 ± 80.2 81.9 ± 122.9 0.19
pH, arterial 7.29 ± 0.16 7.32 ± 0.15 0.19
Continuous data are presented as means ± standard deviation and categorical data as number (%). Clinical or laboratory parameters were measured at initiation of
RRT unless otherwise specified. aPatients for whom data not available were excluded from the computed means
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Outcomes
All-cause mortality at 30 days was 54 % and 61 % among
SLED- and CRRT-treated patients, respectively. After ad-
justment for possible confounders, SLED was not associ-
ated with 30-day mortality (adjusted OR 1.07, 95 % CI
0.56–2.03), as compared with CRRT (Table 3, Fig. 2). Add-
itionally, there were no differences in secondary outcomes
between the groups, including the adjusted risk of RRT
dependence at 30 days and clinical deterioration within
48 h of RRT initiation (Table 4). Cumulative fluid removal
at seven days was not significantly different between the
groups (5846.5 ± 8855.6 mL versus 8180.2 ± 11322.0 mL,
respectively).
Subgroup and sensitivity analyses
There was no association between RRT modality and
mortality within strata of acute illness severity (SOFA ≥
vs. < 16, Table 4).
We repeated the primary analysis with re-categorization
of patients according to the RRT modality received for the
majority of treatment sessions during the first 30 days.
SLED was not significantly associated with 30-day mortality
[adjusted OR 1.70, 95 % CI 0.76–3.28]. Similarly, after
restricting our cohort to patients who received a consistent
modality during the first three treatment sessions (n = 183),
we did not identify a relationship between SLED and 30-
day mortality [adjusted OR 1.36, 95 % CI 0.61–3.82]
(Table 4).
Discussion
In critically ill patients with AKI and hemodynamic in-
stability, the initiation of RRT with SLED is not associ-
ated with a different short-term risk of death and RRT
dependence as compared to the use of CRRT. These
findings were robust after adjustment for demographics,
comorbidities, illness severity, and baseline renal func-
tion and in various sensitivity analyses.
Our results are congruent with those of previous ob-
servational studies. Marshall et al used a time-series ap-
proach to examine mortality rates after a unit-wide
switch at 3 hospitals from CRRT to SLED (referred to as
‘Prolonged Intermittent Renal Replacement Therapy’ or
PIRRT in that study) with SLED administered using
comparable parameters to those described in this study.
The transition to SLED was not associated with in-
creased mortality [8]. Sun et al completed a retrospect-
ive analysis of 65 patients treated with CRRT and 80
treated with SLED and also observed no significant
Table 2 Descriptors of RRT treatments
Variable CRRT SLED
Number of treatments 698 409
Median treatment time (hrs) [IQR] 20.3 [19.0—24.0] 7.11 [6.00—7.92]
Mean proportion of prescribed treatment time delivered (hrs) [SD] 0.85 [0.22] 0.92 [0.17]
Mean blood flow rate (mL/min) 160.2 [56.2] 216.9 [30.1]
Mean effluent flow (mL/kg/hr) 27.2 [10.7] ---
Anticoagulationa (%):
heparin 166 (24.7) 56 (13.8)
citrate 469 (69.7) 0 (0.00)
none 38 (5.6) 350 (86.2)
Per treatment analysis (each patient could have received multiple treatment sessions)
aData not available for 28 treatments (25 CRRT and 3 SLED)
Table 3 Mortality at 30 days
Variable Unadjusted odds ratio (95 % CI) Adjusted odds ratio (95 % CI)
SLED (versus CRRT) 0.74 (0.42–1.29) 1.07 (0.56–2.03)
Age 1.00 (0.98–1.01) 1.01 (0.99–1.03)
Male 0.74 (0.43–1.27) 0.85 (0.45–1.59)
Medical-Surgical or Trauma-Neurosurgical ICU vs Cardiovascular/CCU 1.29 (0.74–2.26) 1.10 (0.57–2.12)
Charlson score 1.08 (0.96–1.21) 1.12 (0.97–1.29)
SOFA score at RRT initiation 1.27 (1.16–1.39) 1.37 (1.20–1.56)
Mechanical ventilation 1.31 (0.49–3.52) 0.67 (0.20–2.27)
Receiving vasopressor 1.65 (0.80–3.40) 0.44 (0.17–1.14)
Serum creatinine at RRT initiation, per 50 μmol/L 0.87 (0.79-0.96) 0.93 (0.83-1.05)
Urine output at RRT initiation, per 100 mL/day 0.97 (0.93–1.02) 0.98 (0.93-1.03)
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difference in 60-day mortality. There was, however, a
higher likelihood of RRT independence in the CRRT
group [19].
Two randomized trials have compared SLED and
CRRT though their findings do not clearly demonstrate
the superiority of either modality. Abe et al randomized
60 patients to SLED or CRRT and found no significant
difference in survival to ICU discharge or 30-day sur-
vival (whichever occurred first) [20]. In-hospital renal re-
covery was not affected by RRT modality. In the largest
clinical trial to compare SLED and CRRT with respect
to clinical outcomes, Schwenger et al randomized 232
critically ill patients with AKI to CRRT or SLED and
found no difference in survival [13]. Importantly, the
mean SLED and CRRT durations achieved were similar
at 14.9 ± 4.4 hrs/session and 15.9 ± 4.2 hrs/session, re-
spectively, which are atypical for the modalities being
compared. In the current study, treatment durations for
SLED and CRRT differed substantially, (7.10 ± 1.9 hrs
and 20.3 ± 5.3 hrs, respectively) and align well with
traditional descriptions of SLED and CRRT [7, 9, 12]. In
our CRRT group, the mean effluent prescribed was
27 mL/kg/hr which is compatible with prevailing recom-
mendations [21].
Kidney recovery, fluid removal and anticoagulation
It has been hypothesized that after AKI, autoregulation of
blood flow is impaired, with susceptibility to further kid-
ney damage as a result of dialysis-related hemodynamic
instability [22, 23]. CRRT has the purported benefit of
improved hemodynamic tolerability compared to IHD [1,
2, 24]. Long-term kidney outcomes may also be better
among patients who received CRRT [24–26]. Although
we demonstrated that surviving SLED recipients are not
more likely to remain RRT-dependent as compared to
CRRT recipients, our sample size is small and the relative
impact of SLED on long-term kidney function is an im-
portant question for future study.
Our findings also demonstrated comparable volume
control among SLED and CRRT recipients in the week
after RRT initiation and support the findings of previous
smaller observational studies [7, 27].
Since the need for anticoagulation often presents a
series of practical challenges in critically ill patients who
require RRT, our finding that the vast majority of SLED
sessions could be delivered with no anticoagulation is
compelling. Since clinical outcomes of SLED seem com-
parable to CRRT, the ability to deliver RRT without the
bleeding and metabolic complications of current anticoa-
gulation options commonly used in CRRT (e.g., heparin
or regional citrate anticoagulation) may represent a major
benefit of SLED. Delivery of SLED predominantly without
anticoagulation has not been reported in other studies
assessing this modality [13, 19, 20, 28].
Strengths and limitations
Our study’s strengths include use of a robust database that
comprises clinically relevant measures of comorbidity,
baseline renal function, biochemical and hemodynamic
Fig. 2 30-day Mortality, RRT Dependence and Early Clinical Deterioration by RRT Modality
Table 4 Secondary outcomes, subgroup and sensitivity analyses
Secondary outcome Unadjusted odds
ratio (95 % CI)
Adjusted odds
ratio (95 % CI)
RRT dependence at 30 days 1.27 (0.53–3.04) 1.36 (0.51–3.57)
Composite outcome: increase
in SOFA score or death at 48 h
0.77 (0.44–1.35) 0.73 (0.40–1.34)
Subgroup analysisa Adjusted odds
ratio (95 % CI)
SOFA score ≥16 1.44 (0.52–3.95)
SOFA score <16 0.84 (0.34–2.11)
Sensitivity analysisb
SLED as predominant RRT
modality
1.70 (0.75–3.82)
SLED as exclusive RRT modality
in first 3 treatment sessions
1.36 (0.61–3.82)
a30-day mortality for patients stratified by SOFA score
b30-day mortality for patients with exposure defined by modality of majority
of RRT treatment sessions received and patients with no change in RRT
modality within the initial three RRT sessions
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indices, and acute illness severity. This enabled us to ad-
just for critical confounders of the relationship between
RRT modality and outcomes and at least partially over-
come bias related to factors that may influence a clinician
to initiate RRT with either SLED or CRRT. Our study
included assessment of early clinical deterioration (within
the first 48 h after RRT initiation), which, to date has not
been examined in the literature and showed that SLED
recipients did not experience a more rapid clinical decline
during the critical period after RRT initiation. Our study
was also conducted in a centre where both SLED and
CRRT were readily available treatment options. This
allowed us to compare contemporaneous patients, rather
than historical controls, as occurs in situations when hospi-
tals make wholesale switches from one modality to the
other. Finally, given that our study is, to our knowledge,
the largest non-randomized comparison of SLED and
CRRT and comprised critically ill patients with AKI from a
variety of causes, we expect that our results will have broad
generalizability and complement information gleaned from
previous smaller studies. As such, we believe that this ob-
servational study provides vital “real world” information
that encompasses a broader spectrum of patients that
might be enrolled in clinical trials.
Our study also has evident limitations. As a non-
randomized study, our findings are susceptible to un-
measured confounding. Given the greater pre-existing
experience and comfort level with CRRT, it is possible
that patients with more severe illness were treated with
CRRT preferentially over SLED. This is suggested by the
slightly higher SOFA and Charlson scores and the higher
frequency of mechanical ventilation in the CRRT group.
These statistically significant differences may bias clinical
outcomes in favour of SLED. In order to mitigate the
impact of confounding, we included multiple measures
of pre-morbid health and acute illness severity in our
multivariable model. After adjustment for these imbal-
ances, the receipt of SLED was not associated with infer-
ior outcomes. The primary analysis examined patients
based on the initial RRT modality received; however, we
recognized that patients could have been treated with
both modalities, which would bias our results towards
the null hypothesis (or no effect). It was therefore re-
assuring that our sensitivity analyses were consistent
with our primary analysis. Our study was restricted to
30-day follow-up and as a result, we were unable to
comment on mortality or RRT dependence associated
with either modality over the long-term. It has been ar-
gued that the nephroprotective benefits of CRRT only
become evident 90 days or more after initiation of RRT,
once the acute illness has abated [25, 26]; however such
long-term data on SLED-treated patients remains limited.
Finally, although the current study is among the largest to
compare SLED and CRRT with respect to clinical
outcomes, our sample size is still too small to definitively
evaluate whether SLED is non-inferior to CRRT.
Conclusions
Our observational data suggest that treatment with SLED
is associated with mortality and short-term renal recovery
that is comparable to CRRT. Pending the completion of an
adequately-powered randomized trial that will evaluate the
impact of SLED on clinical outcomes, SLED appears to be
an acceptable alternative to CRRT for hemodynamically
unstable patients with AKI.
Key messages
– Treatment with SLED was associated with
comparable 30-day mortality and short-term RRT
dependence to CRRT.
– Indicators of clinical status, including change in
SOFA score within 48-h and fluid removal achieved
within seven days, were similar for SLED- and
CRRT-treated patients
– SLED can be readily performed for most patients
without systemic or regional anticoagulation.
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